Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Addex Therapeutics ( (CH:ADXN) ) has shared an update.
Addex Therapeutics announced that its 2025 Annual General Meeting will be held on June 24, 2025, in Geneva. The agenda includes approval of financial statements, re-elections of board members, and compensation approvals. This meeting is significant for stakeholders as it addresses key governance and financial decisions that could impact the company’s strategic direction and investor confidence.
More about Addex Therapeutics
Addex Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of novel small molecule allosteric modulators for neurological disorders. Their lead drug candidate, dipraglurant, is being evaluated for brain injury recovery, and they are also advancing programs for substance use disorders and chronic cough. Addex holds a 20% equity interest in Neurosterix LLC, which is developing treatments for schizophrenia, mood disorders, and mild neurocognitive disorders. The company’s shares are listed on the SIX Swiss Exchange and NASDAQ.
Average Trading Volume: 174,036
Current Market Cap: CHF10.88M
For a thorough assessment of ADXN stock, go to TipRanks’ Stock Analysis page.